infectious diseases Archives -

According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most

How the WHO hepatitis strategy measures up in the field

https://pharmaphorum.com/partner-content/how-the-who-hepatitis-strategy-measures-up-in-the-field/

Market Access/ News/ News/ News/ R&D

Basilea preps key US filing for MRSA antibiotic ceftobiprole

Phil Taylor antibiotic, Basilea, ceftobiprole, infectious diseases, MRSA, Zevtera 0 Comment

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years

Basilea preps key US filing for MRSA antibiotic ceftobiprole

https://pharmaphorum.com/news/basilea-preps-key-us-filing-for-mrsa-antibiotic-ceftobiprole/

Market Access/ News/ News/ News/ Patients

GSK pledges £1bn drive for infectious disease R&D

Phil Taylor developing countries, GlaxoSmithKline, HIV, infectious diseases, Malaria, Novartis, patients, tropical diseases, tuberculosis 0 Comment

GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious

GSK pledges £1bn drive for infectious disease R&D

https://pharmaphorum.com/news/gsk-pledges-1bn-drive-for-infectious-disease-rd/

Events/ Events/ R&D

2nd Annual mRNA-Based Therapeutics Summit

Serena Pickford Phimmai Biotech, coronavirus, COVID-19, infectious diseases, vaccine 0 Comment

Accelerating platforms for mRNA vaccines

2nd Annual mRNA-Based Therapeutics Summit

https://pharmaphorum.com/events/2nd-annual-mrna-based-therapeutics-summit/

Infected female deer tick on hairy human skin. Ixodes ricinus. Dangerous mite detail. Acarus. Infectious borreliosis

News/ News/ R&D

Readout sets up phase 3 for Valneva/Pfizer’s Lyme disease jab

Phil Taylor infectious diseases, Lyme disease, Pfizer, vaccine, Valneva 0 Comment

There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer’s VLA15

Readout sets up phase 3 for Valneva/Pfizer’s Lyme disease jab

https://pharmaphorum.com/news/readout-sets-up-phase-3-for-valneva-pfizers-lyme-disease-jab/

Market Access/ News/ News/ News/ R&D

Cidara and Mundipharma prep filings for antifungal rezafungin

Phil Taylor antifungal, Cidara Therapeutics, infectious diseases, Mundipharma, rezafungin 0 Comment

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal

Cidara and Mundipharma prep filings for antifungal rezafungin

https://pharmaphorum.com/news/cidara-and-mundipharma-prep-filings-for-antifungal-rezafungin/

Events/ Events/ Oncology

The Protein Degradation & Targeting Undruggables Congress

Sarah Rowlands Biotech, clinical trials, infectious diseases, Oncology, pharma 0 Comment

Protein Degradation Event

The Protein Degradation & Targeting Undruggables Congress

https://pharmaphorum.com/events/the-protein-degradation-targeting-undruggables-congress/

Digital/ Events/ Events

3rd Inflammasome Therapeutics Summit

jenna.warren@hansonwade.com drug discovery, immuno-oncology, infectious diseases, inflammasome, innate immunity 0 Comment

Targeting the Inflammasome

3rd Inflammasome Therapeutics Summit

https://pharmaphorum.com/events/3rd-inflammasome-therapeutics-summit/

Partner content/ Patients/ Press releases

Taking a de-centralized approach to cure the Hepatitis C epidemic

Fishawack Marketing dermatology, Hepatitis, infectious diseases, patient centricity, patients 0 Comment

We compare approaches to combatting Hepatitis C

Taking a de-centralized approach to cure the Hepatitis C epidemic

https://pharmaphorum.com/partner-content/taking-a-de-centralized-approach-to-cure-the-hepatitis-c-epidemic/

Trending

infectious diseases

Login